Hermans, Lucas Etienne, Svicher, Valentina, Pas, Suzan Diepstraten, Salpini, Romina ORCID: 0000-0002-2488-2082, Alvarez, Marta, Ben Ari, Ziv, Boland, Greet, Bruzzone, Bianca, Coppola, Nicola, Seguin-Devaux, Carole ORCID: 0000-0003-0636-5222, Dyda, Tomasz, Garcia, Federico ORCID: 0000-0001-7611-781X, Kaiser, Rolf, Kose, Sukran, Krarup, Henrik ORCID: 0000-0001-5294-2428, Lazarevic, Ivana ORCID: 0000-0001-6795-1378, Lunar, Maja M., Maylin, Sarah, Micheli, Valeria ORCID: 0000-0001-5629-3875, Mor, Orna, Paraschiv, Simona, Paraskevis, Dimitrios ORCID: 0000-0001-6167-7152, Poljak, Mario, Puchhammer-Stoeckl, Elisabeth, Simon, Francois, Stanojevic, Maja ORCID: 0000-0002-4643-4272, Stene-Johansen, Kathrine, Tihic, Nijaz, Trimoulet, Pascale, Verheyen, Jens, Vince, Adriana ORCID: 0000-0003-2355-6573, Weis, Nina ORCID: 0000-0002-3133-2724, Yalcinkaya, Tulay, Lepej, Snjezana Zidovec, Perno, Carlo, Boucher, Charles A. B. and Wensing, Annemarie M. J. (2016). Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). J. Infect. Dis., 213 (1). S. 39 - 49. CARY: OXFORD UNIV PRESS INC. ISSN 1537-6613

Full text not available from this repository.

Abstract

European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. A survey was performed on genotypic resistance testing results acquired during routine monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers. Data from 1568 patients were included. The majority (73.8%) were exposed to lamivudine monotherapy. Drug-resistant strains were detected in 52.7%. The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%). In patients exposed to entecavir (n = 102), full resistance was present in 35.3%. Independent risk factors for resistance were age, viral load, and lamivudine exposure (P < .001). These findings support resistance testing in cases of apparent NA therapy failure. This survey highlights the impact of exposure to lamivudine and adefovir on development of drug resistance and cross-resistance. Continued use of these NAs needs to be reconsidered at a pan-European level.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hermans, Lucas EtienneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Svicher, ValentinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pas, Suzan DiepstratenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Salpini, RominaUNSPECIFIEDorcid.org/0000-0002-2488-2082UNSPECIFIED
Alvarez, MartaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ben Ari, ZivUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boland, GreetUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bruzzone, BiancaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Coppola, NicolaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seguin-Devaux, CaroleUNSPECIFIEDorcid.org/0000-0003-0636-5222UNSPECIFIED
Dyda, TomaszUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garcia, FedericoUNSPECIFIEDorcid.org/0000-0001-7611-781XUNSPECIFIED
Kaiser, RolfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kose, SukranUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krarup, HenrikUNSPECIFIEDorcid.org/0000-0001-5294-2428UNSPECIFIED
Lazarevic, IvanaUNSPECIFIEDorcid.org/0000-0001-6795-1378UNSPECIFIED
Lunar, Maja M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maylin, SarahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Micheli, ValeriaUNSPECIFIEDorcid.org/0000-0001-5629-3875UNSPECIFIED
Mor, OrnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Paraschiv, SimonaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Paraskevis, DimitriosUNSPECIFIEDorcid.org/0000-0001-6167-7152UNSPECIFIED
Poljak, MarioUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Puchhammer-Stoeckl, ElisabethUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Simon, FrancoisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stanojevic, MajaUNSPECIFIEDorcid.org/0000-0002-4643-4272UNSPECIFIED
Stene-Johansen, KathrineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tihic, NijazUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trimoulet, PascaleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Verheyen, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vince, AdrianaUNSPECIFIEDorcid.org/0000-0003-2355-6573UNSPECIFIED
Weis, NinaUNSPECIFIEDorcid.org/0000-0002-3133-2724UNSPECIFIED
Yalcinkaya, TulayUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lepej, Snjezana ZidovecUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Perno, CarloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boucher, Charles A. B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wensing, Annemarie M. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-292875
DOI: 10.1093/infdis/jiv363
Journal or Publication Title: J. Infect. Dis.
Volume: 213
Number: 1
Page Range: S. 39 - 49
Date: 2016
Publisher: OXFORD UNIV PRESS INC
Place of Publication: CARY
ISSN: 1537-6613
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
COST-EFFECTIVENESS; REDUCED ANTIGENICITY; LAMIVUDINE TREATMENT; POLYMERASE GENE; PRIOR EXPOSURE; ENTECAVIR; MUTATIONS; TENOFOVIR; HBV; CONSEQUENCEMultiple languages
Immunology; Infectious Diseases; MicrobiologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/29287

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item